Table 1.
Characteristics of included studies.
| Author name | Research center | Patient number | treatment Duration (weeks) | Disease duration (years) | Intervention | Number randomized | HbA1c (%) | Body weight (kg) | Age (Years) | Male N/% |
|---|---|---|---|---|---|---|---|---|---|---|
| Rosenstock (24) | India, Japan, Mexico, USA | 363 | 40 | 4.6 | TZP 5 mg | 121 | 8.0 | 87.0 | 54.1 | 56/46 |
| 4.9 | TZP 10 mg | 121 | 7.9 | 86.2 | 55.8 | 72/60 | ||||
| 4.8 | TZP 15 mg | 121 | 7.9 | 85.4 | 52.9 | 63/52 | ||||
| Dahl (25) | USA, Japan, Czech Republic, Germany, Poland, Slovakia, Puerto Rico, Spain | 355 | 40 | 14.1 | TZP 5 mg | 116 | 8.3 | 95.5 | 62 | 61/53 |
| 12.6 | TZP 10 mg | 119 | 8.3 | 95.4 | 60 | 72/61 | ||||
| 13.7 | TZP 15 mg | 120 | 8.2 | 96.2 | 61 | 65/54 | ||||
| Del (26) | Argentina, Australia, Brazil, Canada, Greece, Israel, Mexico, Poland, Romania, Russia, Slovakia, Spain, Taiwan, USA | 995 | 52 | 9.8 | TZP 5 mg | 329 | 8.5 | 90.3 | 62.9 | 198/60 |
| 10.6 | TZP 10 mg | 328 | 8.6 | 90.6 | 63.7 | 209/64 | ||||
| 10.4 | TZP 15 mg | 338 | 8.5 | 90.0 | 63.7 | 203/60 | ||||
| Ludvik (27) | Argentina, Austria, Greece, Hungary, Italy, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Ukraine, USA | 1,077 | 52 | 8.5 | TZP 5 mg | 358 | 8.2 | 94.4 | 57.2 | 200/56 |
| 8.4 | TZP 10 mg | 360 | 8.2 | 93.8 | 57.4 | 195/54 | ||||
| 8.5 | TZP 15 mg | 359 | 8.2 | 94.9 | 57.5 | 194/54 | ||||
| Frias (28) | USA, UK, Argentina, Australia, Brazil, Canada, Israel, Mexico, | 1,409 | 40 | 9.1 | TZP 5 mg | 470 | 8.3 | 92.5 | 56.3 | 205/43 |
| 8.4 | TZP 10 mg | 469 | 8.3 | 94.8 | 57.2 | 238/50 | ||||
| 8.7 | TZP 15 mg | 470 | 8.3 | 93.8 | 55.9 | 214/45 | ||||
| Frias (29) | Poland, Slovakia, Puerto Rico, USA | 159 | 26 | 8.9 | TZP 5 mg | 55 | 8.2 | 92.8 | 57.9 | 34/62 |
| 7.9 | TZP 10 mg | 51 | 8.2 | 92.7 | 56.5 | 30/59 | ||||
| 8.5 | TZP 15 mg | 53 | 8.1 | 89.1 | 56.0 | 22/42 |